JPRN-UMIN000012909已完成2 期
A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancer - A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancer(KBCSG-TR1315)
Kinki Breast Cancer Study Group-Translational Research (KBCSG-TR)0 个研究点目标入组 120 人开始时间: 2014年1月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Hypersensitivity to any agents necessary in the planned treatment. 2)Poorly controlled complication. 3)Active infectious disease or Fever with suspected infection. 4)Symptoms of varicella. 5)Serious edema. 6)Serious peripheral neuropathy. 7)Positive for HBs antigen, except for not under the appropriate antiviral medication 8)Complication which requires prior pre-treatment with corticosteroid. 9)Previous history or receiving treatment of dementia or serious psychiatric disorder. 10)Heterochrony or synchronous bilateral breast cancer excluding contralateral non-invasive cancer (DCIS/LCIS). 11)Active multiple cancer (Non-invasive tumor or disease free periods after treatment are more than two years, considered to be non-activity). 12)Treatment with anticancer agent within five years. 13)Ineligible based on decision of an investigator.
研究者
相似试验
已完成
2 期
A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancerHER2 negative operable breast cancerJPRN-UMIN000008085Kinki Breast Cancer Study Group-Translational Research (KBCSG-TR)60
已完成
不适用
Phase II study of neoadjuvant chemotherapy with the FEC followed by weekly nab-Paclitaxel(nanoparticle albumin-bound paclitaxel) for the operable breast cancer (KSCOG-BC07)Breast CancerJPRN-UMIN000010504Department of Surgery Kurume University School of Medicine30
已完成
不适用
PhaseII study of neoadjuvant chemotherapy with the nab Paclitaxel And Trastuzumab followed by FEC for the HER2-positive resectable primary breast cancerHER2 positive resectable primary breast cancerJPRN-UMIN000008465Osaka Breast Cancer Chemo-Endocrine Therapy Study Group30
招募中
不适用
A phase II study of Neoadjuvant chemotherapy plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage ovarian cancer (TRU-D)NeoplasmsKCT0003742Yonsei University Health System, Severance Hospital24
已完成
2 期
A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 in advanced esophageal cancer patients with normal oral intakeesophageal cancerJPRN-UMIN000017153Second Department of Surgery, Wakayama Medical University40